Consorzio per Valutazioni Biologiche e Farmacologiche is involved in the “conect4children” (c4c) project aimed to implement and test a collaborative network for European clinical trials for children.
In the framework of the project, four no-profit clinical trials have selected and will be funded. CVBF will participate in two new no-profit paediatric studies and will be in charge of CRO-like activities. The first study cASPerCF (Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection) intends to provide a prospective validation and clinical evaluation of safety and efficacy of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and aspergillus infection. CVBF will be in charge of monitoring activities and data management.
The second study MOI (Matrix-directed therapy in children with osteogenesis imperfecta) is aimed to establish the Optimal Biologic Dose (OBD) of losartan in 30 children aged 8-17 years with OI (Matrix-directed therapy in children with osteogenesis imperfecta) as well as to determine the changes in proxy efficacy outcomes of bone (mass, architecture and strength) and muscle (strength), and determine changes in quality of life using a validated disease-specific tool. CVBF will deal with the monitoring and archiving activities.
For this reason, CVBF is hiring and has opened a call for new positions for experienced CRAs located all over Europe, to conduct monitoring activities in the context of these multinational paediatric studies. To apply click here.